U.S. Markets close in 5 hrs 40 mins

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.56+0.06 (+0.09%)
As of 10:20AM EDT. Market open.
People also watch
CELGBIIBAMGNBMYREGN
Interactive chart
Previous Close64.50
Open64.47
Bid64.70 x 300
Ask64.71 x 700
Day's Range64.31 - 64.75
52 Week Range63.88 - 88.85
Volume1,241,233
Avg. Volume7,827,619
Market Cap84.36B
Beta0.99
PE Ratio (TTM)6.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.22%)
Ex-Dividend Date2017-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com18 minutes ago

    Gilead Sciences: What's in the Pipeline?

    Gilead Sciences (GILD), however, has not only not participated, its shares have continued to drop in 2017. Gilead Sciences has continued to suffer from declining sales of its hepatitis-C drugs, and concerns about competition in HIV, as well. At the same time, the market is still waiting for Gilead to buy a company to help knock it out of the doldrums.

  • Reuters43 minutes ago

    Gilead's HIV drug meets goal in four late-stage studies

    Gilead Sciences Inc said on Tuesday a combination of its experimental HIV drug with existing therapies met the main goal in four late-stage studies. Gilead, which already has approved treatments for HIV, is pinning its hope on the combination to better compete with Britain's GlaxoSmithKline Plc, which is working on two-drug treatment regimen for controlling the virus behind AIDS. The U.S. drugmaker evaluated the addition of its experimental drug, bictegravir, to emtricitabine/tenofovir alafenamide (FTC/TAF), which are already in use to treat HIV.

  • MarketWatch1 hour ago

    Gilead says four late-stage trials of HIV drug combination met primary endpoints

    Gilead Sciences Inc. said pre-market Tuesday that an HIV drug combination met primary endpoints in four late-stage clinical trials. The company said it plans to file for approval in the U.S. and Europe ...